InnoCentive is now Wazoku.

Learn more

Innovation with Wazoku has no boundaries.

Post a Challenge for your problem today, the platform is available now

  • Wazoku is helping Novartis solve important science, technology and business problems by harnessing the power of Wazoku’s global community of 500,000 problem solvers and Challenge Driven Innovation® methodology.
  • The streamlined process including IP agreements and legal verification is effective, efficient and secure.
  • Follow in the footsteps of NASA, your Novartis colleagues and hundreds more and accelerate your innovation outcomes today!
Book a Consultation to run a FREE Challenge
Crowdsourcing with Wazoku offered Novartis efficiency gains, helped promote dialogue, and tapped into the diverse knowledge from the public. This approach to problem-solving is a GAME CHANGER for business. The high-quality solutions have not only validated our current thinking and approach but are also shaping future activities. Moving forward with a crowdsourcing initiative designed to incorporate novel ideas and broad perspectives from external scientific and entrepreneurial communities into our activities, may expedite otherwise lengthy timelines to achieving results.
// Carlos Peralta VP, Medical Innovation & Customer Engagement Head at Novartis

Recent Novartis problems solved

Awarded

Increasing Awareness and Testing of a Genetic Risk Factor for Cardiovascular Disease

According to the World Health Organization, cardiovascular diseases (CVDs) are the leading cause of death worldwide.

View Challenge
Awarded

Development of a Systems Pharmacology Model

Studying the pharmacological effects of drugs injected into the human eye is difficult because traditional sampling methods are invasive. Therefore, the Seeker desires a computational model that accurately simulates the systems pharmacology of an administered drug.

View Challenge
Awarded

Hypothesis for Causality

An approved medicine has been associated with post-marketing adverse event case reports following administration of the drug in the eye. Novartis is seeking plausible hypotheses for these observations based upon publicly available information.

View Challenge

Unparalleled network

  • Find innovative solutions and transformations faster and more cost effectively
  • Have your team's important obstacles and opportunities tackled from a fresh perspective, from a larger pool of knowledge, from different areas of expertise, locations, cultures and backgrounds
  • A global network of 500,000+ innovators and problem solvers from over 195 countries
  • Comprising PhDs, postdocs, engineers, scientists, entrepreneurs, retired technologists and business leaders

Complete the form to allow us to arrange a first conversation with a Wazoku Consultant about your problem: